James is a Patent Agent with over a decade of life sciences research experience. He assists clients with patent drafting, prosecution, and strategic patent portfolio management. James currently advises leading venture-backed biosciences companies—such as A2 Biotherapeutics—on a broad range of intellectual property matters, helping them navigate complex patent landscapes.

His expertise spans antibody-based therapies, cancer biology, and immunology; advanced technologies such as CRISPR gene-editing and mass spectrometry; and platforms including drug screening, molecular diagnostics, and 3D organoid culture systems. He also has experience with immunotoxins, protein structure-function analysis, extracellular vesicles, mouse models of disease, and cellular therapies.

Before joining Mintz, James served as a postdoctoral fellow at the Johns Hopkins University School of Medicine and participated in the school’s patent law training program. During his fellowship, he prepared patentability assessments for life sciences inventions, drafted freedom-to-operate analyses, and conducted IP due diligence and patent landscape analyses to support strategic portfolio planning. His postdoctoral research included identifying a novel role for cell adhesion in regulating cell metabolism and mitochondrial function in metastatic breast cancer. He also developed an in vitro co-culture system to screen novel compounds for inhibiting brain metastasis and performed pre-clinical drug screens on primary breast cancer organoids to identify potential treatments.

Earlier in his career, as a research associate at a clinical-stage biopharmaceutical company, James developed a phage display screening platform and engineered next-generation immunotoxins to identify novel cancer therapeutics. He conducted pre-clinical evaluations of immunotoxins and contributed to the drafting of U.S. and international patent applications related to this research.

While earning his PhD, James identified a TGFβ-regulated miRNA linked to endothelial cell function during tumor angiogenesis and tumor growth, and presented his findings at three international conferences. He also designed in vivo nanoparticle studies to test novel cancer therapies through the delivery of miRNA, molecular therapeutics, or both to specific cell types, and created mouse models to study extracellular vesicles and endothelial cells in healthy and diseased tissues. He received both predoctoral and postdoctoral fellowship grants from the National Cancer Institute to support his training in fundamental cancer research.